Journal of Critical Care
Volume 24, Issue 1 , Pages 1-4 , March 2009

Have we learned how to relax our patients, by thinking outside the box?

Received 30 July 2008 ,Accepted 18 August 2008.

References 

  1. Griffith HR, Johnson GE. The use of curare in general anesthesia. Anesthesiology. 1942;3:418–420
  2. Beecher HK, Todd DP. A study of the deaths associated with anesthesia and surgery: based on a study of 599,548 anesthesias in ten institutions 1948-1952. Ann Surg. 1954;140-1:2–35
  3. Foldes FF, McNall PG, Borrego-Hinojosa JM. Succinylcholine: a new approach to muscular relaxation in anesthesiology. NEJM. 1952;247-16:596–600
  4. Lee C. Suxamethonium in its fifth decade. Baillière's Clinical Anaesthesiology. 1994;8-2:417–440
  5. Savarese JJ, Kitz RJ. Does clinical anesthesia need new neuromuscular blocking agents?. Anesthesiology. 1975;42-3:236–239
  6. Gyermek L, Lee C, Cho YM, et al. Neuromuscular pharmacology of TAAC3, a new nondepolarizing muscle relaxant with rapid onset and ultrashort duration of action. Anesth Analg. 2002;94-4:879–885
  7. Belmont MR, Lien CA, Tjan J, et al. Clinical pharmacology of GW280430A in humans. Anesthesiology. 2004;100-4:768–873
  8. Durant NN, Marshall IG, Savage DS, et al. The neuromuscular and autonomic blocking activities of pancuronium, Org NC 45, and other pancuronium analogues, in the cat. J Pharm Pharmacol. 1979;31-12:831–836
  9. Kopman AF, Klewicka MM, Kopman DJ, et al. Molar potency is predictive of the speed of onset of neuromuscular block for agents of intermediate, short, and ultrashort duration. Anesthesiology. 1999;90:425–431
  10. Lee C. Conformation, action, and mechanism of action of neuromuscular blocking muscle relaxants. Pharmacol Ther. 2003;98-2:143–169
  11. Katz RL. A nerve stimulator for the continuous monitoring of muscle relaxant action. Anesthesiology. 1969;26-6:832–833
  12. Lee CM. Train-of-4 quantitation of competitive neuromuscular block. Anesth Analg. 1975;54-5:649–653
  13. Durant NN, Nguyen N, Lee C, et al. A comparison of 3,4-diaminopyridine and 4-aminopyridine in the anaesthetized cat. Eur J Pharmacol. 1982;84-3:215–219
  14. Uekama K, Hirayama F. Improvement of drug properties by Cyclodextrins. In:  Wermuth CG editors. The practice of medicinal chemistry, Chapter 38. 2nd ed.. Amsterdam: Academic Press, An imprint of Elsevier Science; 2003;p. 649–673

☆ The authors have in the past received supports for their neuromuscular researches from various sponsors including the present Sponsor, Organon, Inc, now part of Schering-Plough Corporation, owner of sugammadex. One author (CL) is coinvestigator and coinventor of the TAAC3 series of compounds (Anesth Analg. 2002;94-4:879-885; now deactivated), which was in the past sponsored in part by the Sponsor. He is also principal investigator of one of the multicenter studies on sugammadex sponsored by the Sponsor.

PII: S0883-9441(08)00182-2

doi: 10.1016/j.jcrc.2008.08.006

Journal of Critical Care
Volume 24, Issue 1 , Pages 1-4 , March 2009

Article Tools